300485Science Sun PharmSZSE

Beijing Science Sun Pharmaceutical Co., Ltd.

赛升药业

300485

Shenzhen Stock Exchange

BoardChiNext of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE100002110
ListedJune 26, 2015
Websitewww.ssyy.com.cn
IR Emailssyyzqb@ssyy.com.cn
Phone010-67862500
Sourcecninfo.com.cn
AddressNo.8, Xingsheng Street, Economic-technological Development Zone, Beijing

Company Overview

Beijing Science Sun Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2015. The company focuses on the research and development, production, and sales of injections, with a specialization in natural and biotechnology drugs targeting cardiovascular and cerebrovascular diseases, immune diseases, and nervous system disorders. Its notable products include Fibrinogenase Injection, Bozhi Glycopeptide Injection, and Sodium Deoxyribonucleotide Injection, which are recognized as significant contributions to the Chinese pharmaceutical market. The company operates a comprehensive production system that includes small volume injections, lyophilized powder injections, tablets, and capsules, supported by a complete production quality management system. Beijing Science Sun Pharmaceutical has established a strong marketing network across major cities in China, backed by a stable base of cooperative dealers. The company is committed to enhancing its product offerings through ongoing R&D investments in new drug delivery technologies and biotechnological products, positioning itself as a competitive player in the pharmaceutical industry.

AI-generated from company disclosures and CNInfo data.

Company Profile

Through technical innovation and excellent after-sales service, the company rapidly expands its major domestic markets and has strong capabilities in the research and development, production and sales of biological and biochemical drugs. It has strong advantages in research and development and production of biologically active macromolecule drugs with certain activities. The company has established a bio-molecular purification technology platform which is based on the company's core technology; it is in a leading position especially in protein separation and purification technology. The company has mature technologies such as affinity chromatography, monoclonal antibody (domain) purification; molecular digestion, tangential flow membrane separation, high-purity peptide solution concentration, lipid preparation etc. and all these technologies are successfully applied to the company's main products.

35 announcements tracked· Last: July 27, 2026

Key Financials

Revenue¥90.4M
Net Profit¥4.7M
ROE0.14%
Debt Ratio4.76%
Monetary Funds¥134.5M
Receivables¥38.9M
Goodwill¥21.9M
Total Shares481.7M

Announcements

35 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.